Match!

Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study

Published on Jan 1, 2018in British Journal of Pharmacology6.58
· DOI :10.1111/bph.14066
Eef L. Theunissen20
Estimated H-index: 20
(UM: Maastricht University),
Nadia R. P. W. Hutten2
Estimated H-index: 2
(UM: Maastricht University)
+ 4 AuthorsJohannes G. Ramaekers40
Estimated H-index: 40
(UM: Maastricht University)
Abstract
Background and Purpose Synthetic cannabinoids (often sold as Spice or K2) have become a very popular alternative to cannabis due to their easy access and portrayed safety. Controlled studies on the behavioural effects of synthetic cannabinoids are currently lacking, which hampers risk assessments of these compounds. Experimental Approach This is a first attempt to assess the influence of a synthetic cannabinoid, JWH-018, on neurocognition and subjective experience in humans after controlled administration. JWH-018, 2 and 3 mg, was administered to six healthy cannabis-experienced volunteers in a placebo-controlled, cross-over study following an escalating dosing schedule. Participants were monitored for 12 h after drug administration, and several neurocognitive measures and subjective questionnaires were taken. Key Results Serum concentrations of JWH-018 were highest after the 2 mg dose but generally low after administration of both doses. Both doses of JWH-018 were well tolerated, and no serious side effects were reported. Participants reported feeling more ‘high’ at 1 and 2 h after administration, particularly after the 2 mg dose. Behavioural impairments also emerged despite the low serum concentrations of JWH-018. The low dose of JWH-018 impaired performance on the tracking, divided attention and stop signal task. Conclusion and Implications JWH-018 dosing in the present study resulted in drug concentrations that were generally low and not fully representative of common use. Yet initial impairments of neurocognitive function and subjective feelings of high did emerge despite low levels of JWH-018 in serum. Higher doses are needed to obtain a more representative risk profile of JWH-018.
  • References (53)
  • Citations (7)
References53
Newest
#1Stephen P.H. Alexander (University of Nottingham)H-Index: 47
#2Arthur Christopoulos (Monash University)H-Index: 63
Last.Joanna L. Sharman (Edin.: University of Edinburgh)H-Index: 8
view all 12 authors...
#1Benjamin M. Ford (University of Arkansas for Medical Sciences)H-Index: 6
#2Sherrica Tai (UM: University of Michigan)H-Index: 6
Last.Paul L. Prather (University of Arkansas for Medical Sciences)H-Index: 28
view all 4 authors...
#1E. B. de Sousa Fernandes Perna (UM: Maastricht University)H-Index: 4
#2Esther Papaseit (Autonomous University of Barcelona)H-Index: 11
Last.Johannes G. Ramaekers (UM: Maastricht University)H-Index: 40
view all 9 authors...
#1A. Vigolo (University of Ferrara)H-Index: 2
#2Andrea Ossato (University of Ferrara)H-Index: 7
Last.Matteo Marti (University of Ferrara)H-Index: 31
view all 9 authors...
#1Andrea Ossato (University of Ferrara)H-Index: 7
#2A. Vigolo (University of Ferrara)H-Index: 2
Last.Matteo Marti (University of Ferrara)H-Index: 31
view all 7 authors...
Cited By7
Newest
#1Hina Akram (UCL: University College London)H-Index: 1
#2Claire Mokrysz (UCL: University College London)H-Index: 9
Last.H. Valerie Curran (UCL: University College London)H-Index: 41
view all 3 authors...
#1Eulàlia Olesti (UPF: Pompeu Fabra University)H-Index: 5
#2Ilario De Toma (UPF: Pompeu Fabra University)H-Index: 1
Last.Oscar J. PozoH-Index: 41
view all 11 authors...
#1P. Muralidhar Reddy (Osmania University)H-Index: 14
#2Nancy Maurya (Rajiv Gandhi Proudyogiki Vishwavidyalaya)H-Index: 1
Last.Bharath Kumar Velmurugan (Ton Duc Thang University)H-Index: 6
view all 3 authors...
#1Stefan W. Toennes (Goethe University Frankfurt)H-Index: 19
#2Anna Geraths (Goethe University Frankfurt)H-Index: 2
Last.Johannes G. Ramaekers (UM: Maastricht University)H-Index: 40
view all 7 authors...
View next paperThe effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration